Assessing the Value of Orphan Drugs Using Conventional Cost-Effectiveness Analysis¶
Nicod, E. (2022). Assessing the Value of Orphan Drugs Using Conventional Cost-Effectiveness Analysis: Is It Fit for Purpose?. Orphanet Journal of Rare Diseases, 17(1).
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Majority-Dominated Aggregate Objective
- Attention and media metrics — aggregate engagement is dominated by median-click contributions; rare-but-important content is starved. Public-health surveillance — aggregate cost-effectiveness measures dominated by common-condition burden divert resources from rare-but-severe events.
This sourceShows conventional cost-per-QALY analysis systematically favors common conditions over rare diseases, diverting resources from rare-but-severe events whose burden is small in aggregate.
- Attention and media metrics — aggregate engagement is dominated by median-click contributions; rare-but-important content is starved. Public-health surveillance — aggregate cost-effectiveness measures dominated by common-condition burden divert resources from rare-but-severe events.
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:bb7776169ca7 · see in the full table